Gilead CEO John Martin says the triple combination HIV pill, to be sold with Bristol-Myers Squibb and Merck, may be on the market this year. Martin says his company will file with the FDA during the second quarter for approval of the drug, the first to combine three HIV medicines in a once-a-day pill.

Related Summaries